IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
This study has been completed.
Sponsor:
Kentuckiana Cancer Institute
Information provided by:
Kentuckiana Cancer Institute
ClinicalTrials.gov Identifier:
NCT00283478
First received: January 26, 2006
Last updated: October 30, 2007
Last verified: October 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
| Condition | Intervention |
|---|---|
| Non-Small Cell Lung Cancer | Drug: Iscar Quercus Drug: Gemcitabine |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs. Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer. |
Resource links provided by NLM:
Genetics Home Reference related topics:
lung cancer
MedlinePlus related topics:
Lung Cancer
U.S. FDA Resources
Further study details as provided by Kentuckiana Cancer Institute:
Primary Outcome Measures:
- To determine if Iscar improves immune function and quality of life.
| Estimated Enrollment: | 20 |
| Study Start Date: | May 2004 |
| Study Completion Date: | April 2007 |
RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
- Karnofsky score 60% or greater
- patients who will be treated with Gemcitabine
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00283478
Please refer to this study by its ClinicalTrials.gov identifier: NCT00283478
Locations
| United States, Kentucky | |
| Kentuckiana Cancer Institute | |
| Louisville, Kentucky, United States, 40202 | |
Sponsors and Collaborators
Kentuckiana Cancer Institute
Investigators
| Study Director: | Renato V. LaRocca, MD | Kentuckiana Cancer Institute |
More Information
| ClinicalTrials.gov Identifier: | NCT00283478 History of Changes |
| Other Study ID Numbers: |
1056757 Mistletoe |
| Study First Received: | January 26, 2006 |
| Last Updated: | October 30, 2007 |
Keywords provided by Kentuckiana Cancer Institute:
|
Advanced stage Lung cancer |
Additional relevant MeSH terms:
|
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Gemcitabine |
Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on September 20, 2017